Adicet Bio, Inc.
General ticker "ACET" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $72.9M (TTM average)
Adicet Bio, Inc. follows the US Stock Market performance with the rate: 16.5%.
Estimated limits based on current volatility of 5.5%: low 0.54$, high 0.60$
Factors to consider:
- Total employees count: 152 (+6.3%) as of 2024
- Top business risk factors: Regulatory and compliance, Strategic risks and growth management, Labor/talent shortage/retention, Development risks, Logistics and manufacturing risks
- Current price 16.9% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.67$, 2.19$]
- 2025-12-31 to 2026-12-31 estimated range: [0.73$, 2.32$]
Financial Metrics affecting the ACET estimates:
- Positive: with PPE of -0.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -115.05 <= 0.33
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 84.74 > 63.39
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ACET quotes
Long-term ACET plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $24.99MM | $0.00MM | $0.00MM |
| Operating Expenses | $97.54MM | $152.04MM | $127.61MM |
| Operating Income | $-72.55MM | $-152.04MM | $-127.61MM |
| Non-Operating Income | $2.76MM | $9.38MM | $10.49MM |
| Interest Expense | $0.08MM | $0.03MM | $0.00MM |
| R&D Expense | $71.25MM | $106.04MM | $99.32MM |
| Income(Loss) | $-69.79MM | $-142.66MM | $-117.12MM |
| Other Income(Loss) | $0.00MM | $0.00MM | $0.02MM |
| Profit(Loss)* | $-69.79MM | $-142.66MM | $-117.12MM |
| Stockholders Equity | $292.34MM | $170.18MM | $186.61MM |
| Assets | $330.69MM | $207.29MM | $220.22MM |
| Operating Cash Flow | $-44.77MM | $-93.72MM | $-92.38MM |
| Capital expenditure | $16.78MM | $4.46MM | $1.12MM |
| Investing Cash Flow | $-16.78MM | $-4.46MM | $-119.24MM |
| Financing Cash Flow | $41.51MM | $0.24MM | $111.31MM |
| Earnings Per Share** | $-1.70 | $-3.31 | $-1.33 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.